Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q3 2020 (← Previous) (Next →)

Filing Date: Nov 16, 2020

Total Value: $3.62B (100.0% shares, 0.0% debt)

Holdings (8)

MRNA Moderna Inc 60.3%

Value $2.184B Shares 30,871,524 Est. Cost $16.43 Unrealized +324.3%

— Seres Therapeutics Inc 16.9%

Value $611M Shares 21,571,764 Est. Cost $8.55 Unrealized —

KLDO Kaleido Biosciences Inc 5.9%

Value $214M Shares 19,360,710 Est. Cost $13.03 Unrealized -46.9%

DNLI Denali Therapeutics Inc 5.9%

Value $214M Shares 5,980,263 Est. Cost $17.97 Unrealized +67.6%

— Rubius Therapeutics Inc 5.3%

Value $192M Shares 38,296,526 Est. Cost $24.00 Unrealized —

— Evelo Biosciences Inc 3.3%

Value $121M Shares 22,900,069 Est. Cost $10.39 Unrealized —

— Axcella Health Inc 1.6%

Value $57.97M Shares 12,548,414 Est. Cost $8.17 Unrealized —

— Syros Pharmaceuticals Inc 0.7%

Value $25.98M Shares 2,938,494 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	30,871,524	$2.184B	60.3%	$16.43	+324.3%	COM	60770K107
—	Seres Therapeutics Inc	21,571,764	$611M	16.9%	$8.55	—	COM	81750R102
KLDO	Kaleido Biosciences Inc	19,360,710	$214M	5.9%	$13.03	-46.9%	COM	483347100
DNLI	Denali Therapeutics Inc	5,980,263	$214M	5.9%	$17.97	+67.6%	COM	24823R105
—	Rubius Therapeutics Inc	38,296,526	$192M	5.3%	$24.00	—	COM	78116T103
—	Evelo Biosciences Inc	22,900,069	$121M	3.3%	$10.39	—	COM	299734103
—	Axcella Health Inc	12,548,414	$57.97M	1.6%	$8.17	—	COM	05454B105
—	Syros Pharmaceuticals Inc	2,938,494	$25.98M	0.7%	$13.87	—	COM	87184Q107